Clinical trials: 2019-nCoV
Coronavirus
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.
In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000…
- Trial name
- Cov-CONTACT (NCT04259892)
- Testing
- 2019-nCoV PCR
- Where
- 16 sites in France, French Guiana
- Volunteers
- 324 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID-19 Vaccine
ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The goals of this clinical trial are: 1. Phase 2: to test a gamma adapted recombinant vaccine against SARS-CoV-2 in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus. 2.
- Trial name
- ARVAC-F2/3 (NCT05752201)
- Testing
- Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine, Bivalent RBD-based ARVAC-CG vaccine
- Where
- 11 sites in Argentina
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
COVID-19, Corona Virus Infection
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV
- Trial name
- NCT04334967
- Testing
- Hydroxychloroquine, Vitamin C
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Healthy Participant
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
A study to learn how the study medicine called Ibuzatrelvir is taken up into the blood in healthy Chinese adults.
- Trial name
- NCT07235137
- Testing
- Ibuzatrelvir
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
2019-nCoV
Prognositc Factors in COVID-19 Patients Complicated With Hypertension
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.
- Trial name
- NCT04272710
- Where
- China
- Sponsor
- Chongqing Medical University
COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2
Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
This is a multicentre, open-label Phase 1/2 study, with a first-in-human (FIH) dose escalation part (Phase 1 study) followed by an open-label single arm (or two-arms, randomized) dose expansion part (Phase 2 study).
- Conditions
- COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2, COVID-19 Immunisation
- Trial name
- NCT04788459
- Testing
- COVID-eVax, Cliniporator® and EPSGun
- Where
- 4 sites in Italy
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Takis
Hypertension, COVID-19
Coronavirus (COVID-19) ACEi/ARB Investigation
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- CORONACION (NCT04330300)
- Testing
- Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor
- Where
- Ireland
- Volunteers
- 2,414 people
- Sponsor
- National University of Ireland, Galway, Ireland
COVID-19, Coronavirus 2019
Genetics of COVID-19 Susceptibility and Manifestations
Background: Coronavirus 2019 (COVID-19, or SARS-CoV-2) is a serious public health problem, and genetics may play a role in how serious the illness becomes in certain people.
- Trial name
- NCT04371432
- Where
- United States
- Volunteers
- 721 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Immunophenotyping Assessment in a COVID-19 Cohort
This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify…
- Trial name
- IMPACC (NCT04378777)
- Testing
- Biological sample collection, Data Collection: Clinical Care Assessments
- Where
- 17 sites in United States
- Volunteers
- 1,227 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Infectious Disease 2019 (COVID-19)
COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)
This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleic acid analysis platform from, but not limited to, saliva to help enable and support contact tracing in the canton of Baselland/ Switzerland.
- Trial name
- NCT04625257
- Testing
- Saliva based assay: crude RNA extraction, Validation of the NGS method, Validation of the LAMP assays
- Where
- Switzerland
- Volunteers
- 1,600 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
Aerosol Combination therapy of All-trans retinoic acid and Isotretinoin as A novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients better than vaccine : An innovative Treatment Mahmoud…
- Trial name
- Antibodies (NCT04396067)
- Testing
- Aerosolized 13 cis retinoic acid, Aerosolized All trans retinoic acid
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Covid19, SARS-CoV2 Infection
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- Conditions
- Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
- Trial name
- NCT05047783
- Testing
- Masitinib Mesylate
- Where
- 6 sites in France, Russia and 1 more
- Volunteers
- 78 people
- Sponsor
- AB Science
Covid19
Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.
The main purpose of this study is to identify possible predictor factor of mortality in patients affected by COVID-19 with respiratory failure needing oxygen therapy or ventilatory support.
- Trial name
- NCT04552340
- Testing
- Patient with SAR-CoV-2 infection
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Istituto Clinico Humanitas
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
COVID-19, Pneumonia
A Study of LY3127804 in Participants With COVID-19
A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19.
- Trial name
- NCT04342897
- Testing
- LY3127804
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Death; Major Adverse Cardiovascular Events
2019-nCoV Outbreak and Cardiovascular Diseases
Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last…
- Trial name
- NCT04255940
- Where
- 12 sites in China
- Volunteers
- 12,000 people
- Sponsor
- Qilu Hospital of Shandong University
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Coronavirus
Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)
This multi-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 40 patients aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in…
- Trial name
- CX4945 (NCT04668209)
- Testing
- Silmitasertib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Arizona